Home
>
US Stocks
>
Standard BioTools Inc

Standard BioTools Inc (LAB)

$2.35

-0.1

(-4.08%)▲

Market is closed - opens 7 PM, 01 Jun 2023

Insights on Standard BioTools Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 27.02M → 25.11M (in $), with an average decrease of 7.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 5 quarters, -76.28M → -16.84M (in $), with an average increase of 50.2% per quarter

  • Vs IDXX

    In the last 3 years, Idexx Laboratories, Inc. has given 50.9% return, outperforming this stock by 94.7%

Performance

  • $2.32
    $2.47
    $2.35
    downward going graph

    1.28%

    Downside

    Day's Volatility :6.07%

    Upside

    4.86%

    downward going graph
  • $0.92
    $2.65
    $2.35
    downward going graph

    60.85%

    Downside

    52 Weeks Volatility :65.28%

    Upside

    11.32%

    downward going graph

Returns

PeriodStandard BioTools IncSector (Health Care)Index (Russel 2000)
3 Months
34.62%
-0.3%
-6.7%
6 Months
76.26%
-8.8%
-6.2%
1 Year
29.63%
-4.2%
-5.1%
3 Years
-37.66%
23.0%
26.9%

Highlights

Market Capitalization
195.2M
Book Value
- $1.24
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.6
Wall Street Target Price
0.7
Profit Margin
-135.3%
Operating Margin TTM
-104.29%
Return On Assets TTM
-19.56%
Return On Equity TTM
-110.62%
Revenue TTM
96.6M
Revenue Per Share TTM
1.23
Quarterly Revenue Growth YOY
-5.2%
Gross Profit TTM
-1.4M
EBITDA
-97.4M
Diluted Eps TTM
-1.6
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.01
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 5 Wall street analysts offering stock ratings for Standard BioTools Inc(by analysts ranked 0 to 5 stars)
Based on 5 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
4
4
4
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Downside of 70.21%

Current $2.35
Target $0.70

Company Financials

FY17Y/Y Change
Revenue
101.9M
↓ 2.4%
Net Income
-60.5M
↓ 20.33%
Net Profit Margin
-59.38%
↑ 13.37%
FY18Y/Y Change
Revenue
113.0M
↑ 10.82%
Net Income
-59.0M
↓ 2.51%
Net Profit Margin
-52.24%
↑ 7.14%
FY19Y/Y Change
Revenue
117.2M
↑ 3.79%
Net Income
-64.8M
↑ 9.79%
Net Profit Margin
-55.26%
↓ 3.02%
FY20Y/Y Change
Revenue
138.1M
↑ 17.83%
Net Income
-53.0M
↓ 18.17%
Net Profit Margin
-38.38%
↑ 16.88%
FY21Y/Y Change
Revenue
130.6M
↓ 5.47%
Net Income
-59.2M
↑ 11.73%
Net Profit Margin
-45.36%
↓ 6.98%
FY22Y/Y Change
Revenue
97.9M
↓ 24.99%
Net Income
-190.1M
↑ 220.91%
Net Profit Margin
-194.08%
↓ 148.72%
Q4 FY21Q/Q Change
Revenue
38.3M
↑ 34.24%
Net Income
-9.4M
↓ 31.89%
Net Profit Margin
-24.64%
↑ 23.93%
Q1 FY22Q/Q Change
Revenue
26.5M
↓ 30.74%
Net Income
-76.3M
↑ 709.08%
Net Profit Margin
-287.84%
↓ 263.2%
Q2 FY22Q/Q Change
Revenue
18.8M
↓ 29.15%
Net Income
-63.5M
↓ 16.71%
Net Profit Margin
-338.39%
↓ 50.55%
Q3 FY22Q/Q Change
Revenue
25.6M
↑ 36.58%
Net Income
-29.4M
↓ 53.69%
Net Profit Margin
-114.74%
↑ 223.65%
Q4 FY22Q/Q Change
Revenue
27.0M
↑ 5.36%
Net Income
-20.8M
↓ 29.16%
Net Profit Margin
-77.14%
↑ 37.6%
Q1 FY23Q/Q Change
Revenue
25.1M
↓ 7.04%
Net Income
-16.8M
↓ 19.2%
Net Profit Margin
-67.05%
↑ 10.09%
FY17Y/Y Change
Total Assets
287.4M
↓ 6.22%
Total Liabilities
256.4M
↑ 1.29%
FY18Y/Y Change
Total Assets
303.6M
↑ 5.67%
Total Liabilities
231.5M
↓ 9.7%
FY19Y/Y Change
Total Assets
264.8M
↓ 12.79%
Total Liabilities
111.2M
↓ 51.97%
FY20Y/Y Change
Total Assets
324.8M
↑ 22.64%
Total Liabilities
185.7M
↑ 67.0%
FY21Y/Y Change
Total Assets
275.2M
↓ 15.26%
Total Liabilities
180.6M
↓ 2.74%
FY22Y/Y Change
Total Assets
390.3M
↑ 41.82%
Total Liabilities
160.5M
↓ 11.13%
Q4 FY21Q/Q Change
Total Assets
275.2M
↓ 2.47%
Total Liabilities
180.6M
↓ 1.22%
Q1 FY22Q/Q Change
Total Assets
271.9M
↓ 1.19%
Total Liabilities
249.8M
↑ 38.32%
Q2 FY22Q/Q Change
Total Assets
441.1M
↑ 62.21%
Total Liabilities
167.3M
↓ 33.02%
Q3 FY22Q/Q Change
Total Assets
414.9M
↓ 5.94%
Total Liabilities
166.4M
↓ 0.55%
Q4 FY22Q/Q Change
Total Assets
390.3M
↓ 5.93%
Total Liabilities
160.5M
↓ 3.54%
Q1 FY23Q/Q Change
Total Assets
371.7M
↓ 4.78%
Total Liabilities
157.6M
↓ 1.85%
FY17Y/Y Change
Operating Cash Flow
-24.1M
↓ 38.43%
Investing Cash Flow
17.7M
↓ 60.85%
Financing Cash Flow
29.0M
↑ 24897.41%
FY18Y/Y Change
Operating Cash Flow
-25.2M
↑ 4.58%
Investing Cash Flow
4.7M
↓ 73.28%
Financing Cash Flow
57.7M
↑ 98.85%
FY19Y/Y Change
Operating Cash Flow
-35.2M
↑ 39.72%
Investing Cash Flow
-39.3M
↓ 932.82%
Financing Cash Flow
2.8M
↓ 95.16%
FY20Y/Y Change
Operating Cash Flow
-15.4M
↓ 56.21%
Investing Cash Flow
40.0M
↓ 201.71%
Financing Cash Flow
20.9M
↑ 647.56%
FY21Y/Y Change
Operating Cash Flow
-44.1M
↑ 185.79%
Investing Cash Flow
-11.9M
↓ 129.88%
Financing Cash Flow
16.0M
↓ 23.48%
FY22Y/Y Change
Operating Cash Flow
-89.4M
↑ 102.83%
Investing Cash Flow
-88.1M
↑ 637.71%
Financing Cash Flow
230.8M
↑ 1345.94%
Q4 FY21Q/Q Change
Operating Cash Flow
-7.0M
↓ 26.25%
Investing Cash Flow
-1.1M
↓ 32.88%
Financing Cash Flow
7.3M
↓ 25.7%
Q1 FY22Q/Q Change
Operating Cash Flow
-15.6M
↑ 122.65%
Investing Cash Flow
-868.0K
↓ 24.19%
Financing Cash Flow
18.1M
↑ 147.7%
Q2 FY22Q/Q Change
Operating Cash Flow
-30.0M
↑ 92.35%
Investing Cash Flow
-138.2M
↑ 15826.27%
Financing Cash Flow
213.0M
↑ 1078.19%
Q3 FY22Q/Q Change
Operating Cash Flow
-40.2M
↑ 34.06%
Investing Cash Flow
10.7M
↓ 107.77%
Financing Cash Flow
18.1M
↓ 91.51%
Q4 FY22Q/Q Change
Operating Cash Flow
-89.4M
↑ 122.31%
Investing Cash Flow
-88.1M
↓ 920.86%
Financing Cash Flow
230.8M
↑ 1177.02%
Q1 FY23Q/Q Change
Operating Cash Flow
-8.5M
↓ 90.51%
Investing Cash Flow
43.2M
↓ 148.97%
Financing Cash Flow
-2.6M
↓ 101.11%

Technicals Summary

Sell

Neutral

Buy

Standard BioTools Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Standard BioTools Inc
Standard BioTools Inc
53.13%
76.26%
29.63%
-37.66%
-37.66%
IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
-4.78%
9.47%
19.05%
49.34%
123.92%
Agilent Technologies Inc.
Agilent Technologies Inc.
-13.48%
-24.04%
-7.71%
30.94%
90.13%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-6.25%
-8.21%
-9.4%
47.2%
146.9%
Danaher Corp.
Danaher Corp.
-6.02%
-16.91%
-13.89%
37.37%
128.83%
IQVIA Holdings Inc.
IQVIA Holdings Inc.
4.55%
-8.88%
-7.71%
32.96%
100.8%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Standard BioTools Inc
Standard BioTools Inc
NA
NA
NA
-0.01
-1.11
-0.2
0.0
-1.24
IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
55.23
55.23
7.21
9.69
0.94
0.22
0.0
10.13
Agilent Technologies Inc.
Agilent Technologies Inc.
26.91
26.91
2.36
5.63
0.25
0.1
0.01
18.96
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
34.01
34.01
4.28
23.68
0.14
0.05
0.0
109.55
Danaher Corp.
Danaher Corp.
25.0
25.0
3.24
9.38
0.14
0.06
0.0
68.31
IQVIA Holdings Inc.
IQVIA Holdings Inc.
35.62
35.62
1.48
10.42
0.18
0.05
0.0
31.98
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Standard BioTools Inc
Standard BioTools Inc
Buy
$195.2M
-37.66%
NA
-135.3%
IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
Buy
$38.9B
123.92%
55.23
20.38%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$35.3B
90.13%
26.91
19.09%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$201.4B
146.9%
34.01
13.75%
Danaher Corp.
Danaher Corp.
Buy
$171.3B
128.83%
25.0
22.4%
IQVIA Holdings Inc.
IQVIA Holdings Inc.
Buy
$37.0B
100.8%
35.62
7.28%

Company Information

Fluidigm focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, it develops, manufactures, and markets multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Its customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, the Company strives to increase the quality of life for all.

Organization
Standard BioTools Inc
Employees
523
CEO
Mr. Vikram Jog
Industry
Healthcare

Discover More

FAQs